HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Probiotic Safety Latest Target Of Supplement Regulation Critic Cohen

This article was originally published in The Rose Sheet

Executive Summary

More extensive labeling for probiotics and more stringent GMPs for live microorganism production already are required in Canada, says physician and researcher Pieter Cohen in JAMA Internal Medicine. "Consumers and physicians should not assume that the label on probiotic supplements provides adequate information to determine if consuming the live microorganism is worth the risk," he says.

Advertisement

Related Content

Metric Weights For Probiotics Mislead But CFUs Inform, Say Industry Groups
FDA Regulatory Oversight No Impediment To Drug-Spiked Supplements, Study Finds
Supplement GMP Inspections Slowing As FDA Makes 'Potential' Data Useful
DMAA, Other Stimulants Cast Shadow Over FDA Supplement Regulation – Study
FDA Recalls For Dec. 24, 2014, And Jan. 7, 2015

Topics

Advertisement
UsernamePublicRestriction

Register

RS122561

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel